Emerging drugs for chemotherapy-induced emesis

Expert Opinion on Emerging Drugs
Rudolph M Navari, Paula S Province

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles and patient risk factors (female gender, younger age, no alcohol consumption, history of motion sickness) are the major risk factors for CINV. The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists plus dexamethasone has significantly improved the control of acute CINV, but delayed nausea and vomiting remains a significant clinical problem. Two new agents, palonosetron and aprepitant, have recently been approved for the prevention of both acute and delayed CINV. Palonosetron is a 5-HT3 receptor antagonist with a longer half-life and a higher binding affinity than first-generation 5-HT3 receptor antagonists. Aprepitant is the first agent available in the new drug class of neurokinin-1 receptor (NK-1) antagonists. There are a number of 5-HT3 receptor antagonists and NK-1 receptor antagonists currently in Phase II and III clinical trials. Revised antiemetic guidelines for the prevention of CINV are reviewed. Future studies may consider the use of palonosetron and aprepitant with current and other new agents (olanzapine, gabapentin) i...Continue Reading

References

Feb 1, 1983·Drugs·H L Borison, L E McCarthy
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M NavariK C Caldwell
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E A Perez
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R NavariD Fitts
Oct 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M NavariD Fitts
Jan 5, 1995·The New England Journal of Medicine·UNKNOWN Italian Group for Antiemetic Research
Mar 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethB Haley
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethC M Lindley
Jan 1, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·E A PerezD Fitts
Nov 1, 1996·Drugs·R Tavorath, P J Hesketh
May 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M G KrisS B Chernoff
Jun 4, 1997·Journal of the National Cancer Institute·M G KrisP J Hesketh
Jul 1, 1997·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·D OsobaJ Pater
Jan 1, 1997·Fundamental & Clinical Pharmacology·Y NozawaR Kimura
Jan 1, 1997·British Journal of Cancer·M de Boer-DennertJ Verweij
Mar 21, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J LatreilleB Zee
Jan 7, 1999·European Journal of Pharmacology·M MinamiK Kisara
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P J HeskethS L Silberman
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J GrallaD G Pfister
Dec 22, 1999·Breast Cancer Research and Treatment·E A Perez
May 29, 2000·The New England Journal of Medicine·UNKNOWN Italian Group for Antiemetic Research
Oct 13, 2000·Drugs·P Diemunsch, L Grélot
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D CamposB J Gertz
Apr 21, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V CocquytB J Gertz
Nov 17, 2001·European Journal of Pharmacology·F P BymasterM L Cohen
Sep 27, 2002·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Fausto Roila
Sep 27, 2002·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Jim M KoellerRebecca A Clark-Snow
Mar 6, 2003·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Alessandra FabiFrancesco Cognetti
May 3, 2003·Journal of Pain and Symptom Management·Steven D PassikJustin Brown

❮ Previous
Next ❯

Citations

Apr 9, 2008·The Cancer Journal·Lisa Lohr
Jan 1, 2008·Expert Review of Clinical Pharmacology·Jennifer LarussoWalter K Kraft
Nov 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·Rudolph M Navari
Dec 22, 2007·Expert Opinion on Investigational Drugs·Mellar P Davis
Jul 18, 2008·Supportive Cancer Therapy·Aarati RanganathanDebu Tripathy
Aug 28, 2007·Pharmazie in unserer Zeit·Heiko ZettlCarsten D Siebert
Jun 12, 2008·Journal of Pharmacological Sciences·Yumi WatanabeAkira Saito
May 28, 2016·Journal of Translational Medicine·Jeffrey S BarrettSteven D Douglas
May 29, 2010·The American Journal of Hospice & Palliative Care·Nerissa Licup

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here